Radiation therapy firm Accuray has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its dose control system (DCS) feature for the TomoTherapy treatment system.
The new DCS feature is designed to automatically adjust controls that were previously handled through a manual process, so that variations in dose rate are corrected by the system, resulting in fewer interruptions, according to the firm.
The DCS application also helps to control total marrow and total body irradiation.
